Trial · NCT03890588
Chronic Kidney Disease Clinical Decision Support
NCT03890588, Not applicable, Completed, HealthPartners Institute; results first posted 2022-12-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chronic Kidney Disease Clinical Decision Support. Trials, record NCT03890588. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03890588
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chronic Kidney Disease Clinical Decision Support
- NCT number
- NCT03890588
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 6,295 participants, actual
- Lead sponsor
- HealthPartners Institute
- Conditions
- Chronic Kidney Diseases, Hypertension, Diabetes
- Interventions
- CKD enhanced clinical decision support
- First posted
- 2019-03-26
- Last updated
- 2022-12-01
- Results first posted
- 2022-12-01
- Limitations and caveats
Some Usual Care (UC) participants received CDS for BP and A1c management due to existing CDS pre-dating the study. Due to Corona Virus Disease 2019 (COVID-19), the study paused 5 months, and there were fewer office visits, which would have limited intervention exposure. The intervention didn't allow for video visit screen sharing, a visit type that increased in the pandemic. There was a potential learning effect contamination due to some clinicians caring for patients in both study arms.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With CKD Diagnosis | 18-month period post index | Number of patients who had a CKD diagnosis document in the 18 months post index. |
| Primary | Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB) | 18-month period post index | Number of patients who had an Angiotensin-converting enzyme inhibitors (ACEI) or Angiotension II reception blockers (ARB) order in the 18 months post index. |
| Primary | Number of Patients With Optimal Blood Pressure Control | 18-month period post index | Number of patients for whom the average of the two most recent blood pressures prior to 18 months post index was \<130/80. |
| Primary | Number of Patients With Optimal Glucose Control | 1 to 18-month period post index | Number of patients whose last A1c was \<7% in the 1-18 months post index. |
| Primary | Number of Patients With Referral to Nephrology | 18-month period post index | Number of patients who have a referral to nephrology in the 18 months post index. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With CKD Diagnosis | 18-month period post index | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB) | 18-month period post index | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Patients With Optimal Blood Pressure Control | 18-month period post index | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Patients With Optimal Glucose Control | 1 to 18-month period post index | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Patients With Referral to Nephrology | 18-month period post index | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With CKD Diagnosis | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 417 | Participants | ||
| Number of Participants With CKD Diagnosis | Usual Care | 389 | Participants | ||
| Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB) | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 151 | Participants | ||
| Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB) | Usual Care | 192 | Participants | ||
| Number of Patients With Optimal Blood Pressure Control | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 334 | Participants | ||
| Number of Patients With Optimal Blood Pressure Control | Usual Care | 388 | Participants | ||
| Number of Patients With Optimal Glucose Control | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 141 | Participants | ||
| Number of Patients With Optimal Glucose Control | Usual Care | 159 | Participants | ||
| Number of Patients With Referral to Nephrology | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 92 | Participants | ||
| Number of Patients With Referral to Nephrology | Usual Care | 95 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 2,923 | 16 |
| Overall Study | STARTED | Usual Care | 3,372 | 16 |
| Overall Study | COMPLETED | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 2,923 | 16 |
| Overall Study | COMPLETED | Usual Care | 3,372 | 16 |
| Overall Study | NOT COMPLETED | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 0 | 0 |
| Overall Study | NOT COMPLETED | Usual Care | 0 | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Emergency Room Visits | General disorders | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 1,039 | 2,923 | |
| other | Emergency Room Visits | General disorders | Usual Care | 1,100 | 3,372 | |
| other | hypoglycemia | Endocrine disorders | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 202 | 1,123 | |
| other | hypoglycemia | Endocrine disorders | Usual Care | 232 | 1,263 | |
| other | hypotension | Vascular disorders | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 548 | 2,923 | |
| other | hypotension | Vascular disorders | Usual Care | 814 | 3,372 | |
| other | hypokalemia | Metabolism and nutrition disorders | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 853 | 2,923 | |
| other | hypokalemia | Metabolism and nutrition disorders | Usual Care | 1,061 | 3,372 | |
| other | hyperkalemia | Metabolism and nutrition disorders | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 660 | 2,923 | |
| other | hyperkalemia | Metabolism and nutrition disorders | Usual Care | 847 | 3,372 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 151 | 2,923 |
| Total, all-cause mortality | Usual Care | 175 | 3,372 |
| Total, other adverse events | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 1,039 | 2,923 |
| Total, other adverse events | Usual Care | 1,100 | 3,372 |
| Total, serious adverse events | CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) | 541 | 2,923 |
| Total, serious adverse events | Usual Care | 543 | 3,372 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R18DK118463 | A Technology-Driven Intervention to Improve Identification and Management of Chronic Kidney Disease in Primary Care | SPERL-HILLEN, JOANN M | HEALTHPARTNERS INSTITUTE | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2018 to 2020 |
Source NIH RePORTER
Trial comparisons7
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Optimal Glucose Control | Trial comparisons |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Referral to Nephrology | Trial comparisons |
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB) | Trial comparisons |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Optimal Blood Pressure Control | Trial comparisons |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Participants With CKD Diagnosis | Trial comparisons |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: deaths from any cause | Trial comparisons |
| CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03890588
GET https://conductscience.org/api/trials/v1/NCT03890588/registered